Apricus Biosciences Announces That Its NexACT(R) Partner Exodos Life Sciences Has Completed Its pre-IND Meeting With the FDA

SAN DIEGO, Nov. 15, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) announced today that its NexACT® out-licensing partner, Exodos Life Science Limited Partnership ("Exodos"), a privately-held company located in Chapel Hill, North Carolina, has completed a successful pre-IND ("Investigational New Drug Application") meeting with the U.S. Food and Drug Administration ("FDA") regarding its plan to conduct clinical trials to establish the safety and effectiveness of its patented, topical painkilling drug, ELS115, containing NexACT® technology licensed from Apricus Bio.